Indian multinational pharmaceutical company Zydus Lifesciences Ltd on Wednesday announced that its Typhoid Vi conjugate ...

Zydus Lifesciences' shares rose 2.81% after receiving WHO approval for its indigenously developed typhoid vaccine, ZyVac TCV, ...

Zydus Lifesciences Ltd has received in-principle approval from the WHO for its Typhoid Vi conjugate vaccine, ZyVac TCV.

Ahmedabad: Zydus Lifesciences Limited has announced that it has received in principle acceptability from World Health ...

As per GAVI (2022) it is estimated that Typhoid accounts for an estimated 11 to 21 million cases of febrile illness and ...

Zydus Lifesciences advanced 1.71% to Rs 1,005.05 after the company received in principle acceptability from World Health Organisation (WHO) for its ZyVac TCV vaccine.

ZyVac TCV is designed for active immunization against Salmonella typhi infection in individuals aged 6 months to 65 years.

Approved in India as Oxemia for anemia, desidustat stimulates erythropoietin, a signaling molecule secreted in response to ...

ICMR partners with Zydus Lifesciences for Desidustat phase-2 trials in sickle cell disease patients, aiming for innovative ...

Zydus Lifesciences shares were trading flat on October 18 after the company received final approval to manufacture ...

The Delhi High Court division bench has allowed Zydus Lifesciences to sell its breast cancer drug Sigrima amidst accusations ...